<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395991</url>
  </required_header>
  <id_info>
    <org_study_id>CS_2015_ISS</org_study_id>
    <nct_id>NCT02395991</nct_id>
  </id_info>
  <brief_title>Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI</brief_title>
  <official_title>Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe transient dyspnea pattern after Gd-EOB-DTPA&#xD;
      administration by obtaining continuous dynamic T1 weighted image data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Transient Dyspnea.</measure>
    <time_frame>during 3 minutes after contrast media administration</time_frame>
    <description>A sudden onset irregular breathing pattern after EOB administration, based on MRI k-space data (not participants' symptom).&#xD;
The k-space data was analyzed after the enrollment completion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Transient Dyspnea in Participants With Transient Dyspnea.</measure>
    <time_frame>during 3 minutes after contrast media administration</time_frame>
    <description>The duration of transient dyspnea was analyzed based on the MRI k-space data, using a dedicated software.&#xD;
The analysis using the MRI k-space data was performed after the completion of enrollment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Liver Stiffness Value</measure>
    <time_frame>in three days after MRI</time_frame>
    <description>liver stiffness value from MR elastography using GRE and SE sequence which is a part of protocol.&#xD;
Both GRE and SE sequences are two different sequences for obtaining MR elastogrphy which measures the stiffness of the liver.&#xD;
The measured liver stiffness is known to be related to the degree of hepatic fibrosis and/or inflammation.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Observe1</arm_group_label>
    <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadoxetic acid</intervention_name>
    <description>standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration</description>
    <arm_group_label>Observe1</arm_group_label>
    <other_name>eovist</other_name>
    <other_name>primovist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance imaging (MRI)</intervention_name>
    <description>Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
    <arm_group_label>Observe1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver MRI&#xD;
        using gadoxetic acid.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are referred to MR unit for hepatocyte-specific contrast enhanced liver&#xD;
             MRI using gadoxetic acid, to characterize focal liver lesion or to investigate diffuse&#xD;
             liver disease&#xD;
&#xD;
          -  OR, Liver living donor candidates&#xD;
&#xD;
          -  AND subjects who sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minors under 18 years old&#xD;
&#xD;
          -  All contraindication to MRI&#xD;
&#xD;
          -  Hypersensitivity to Gd&#xD;
&#xD;
          -  Biliary obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <results_first_submitted>November 3, 2018</results_first_submitted>
  <results_first_submitted_qc>May 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 26, 2021</results_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>gadoxetic acid</keyword>
  <keyword>transient dyspnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>April 2015 to October 2015, patients who are referred to Radiology unit in SNUH for liver MRI scan.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>EOB-MRI</title>
          <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)&#xD;
gadoxetic acid: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration&#xD;
Magnetic resonance imaging (MRI): Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observe1</title>
          <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)&#xD;
gadoxetic acid: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration&#xD;
Magnetic resonance imaging (MRI): Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Transient Dyspnea.</title>
        <description>A sudden onset irregular breathing pattern after EOB administration, based on MRI k-space data (not participants' symptom).&#xD;
The k-space data was analyzed after the enrollment completion.</description>
        <time_frame>during 3 minutes after contrast media administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EOB-MRI</title>
            <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)&#xD;
gadoxetic acid: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration&#xD;
Magnetic resonance imaging (MRI): Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transient Dyspnea.</title>
          <description>A sudden onset irregular breathing pattern after EOB administration, based on MRI k-space data (not participants' symptom).&#xD;
The k-space data was analyzed after the enrollment completion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Transient Dyspnea in Participants With Transient Dyspnea.</title>
        <description>The duration of transient dyspnea was analyzed based on the MRI k-space data, using a dedicated software.&#xD;
The analysis using the MRI k-space data was performed after the completion of enrollment.</description>
        <time_frame>during 3 minutes after contrast media administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Observe1</title>
            <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)&#xD;
gadoxetic acid: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration&#xD;
Magnetic resonance imaging (MRI): Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Transient Dyspnea in Participants With Transient Dyspnea.</title>
          <description>The duration of transient dyspnea was analyzed based on the MRI k-space data, using a dedicated software.&#xD;
The analysis using the MRI k-space data was performed after the completion of enrollment.</description>
          <units>second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Liver Stiffness Value</title>
        <description>liver stiffness value from MR elastography using GRE and SE sequence which is a part of protocol.&#xD;
Both GRE and SE sequences are two different sequences for obtaining MR elastogrphy which measures the stiffness of the liver.&#xD;
The measured liver stiffness is known to be related to the degree of hepatic fibrosis and/or inflammation.</description>
        <time_frame>in three days after MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EOB-MRI</title>
            <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)&#xD;
gadoxetic acid: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration&#xD;
Magnetic resonance imaging (MRI): Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Stiffness Value</title>
          <description>liver stiffness value from MR elastography using GRE and SE sequence which is a part of protocol.&#xD;
Both GRE and SE sequences are two different sequences for obtaining MR elastogrphy which measures the stiffness of the liver.&#xD;
The measured liver stiffness is known to be related to the degree of hepatic fibrosis and/or inflammation.</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SE MRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GRE MRE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 hour after MRI completion</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EOB-MRI</title>
          <description>Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)&#xD;
gadoxetic acid: standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration&#xD;
Magnetic resonance imaging (MRI): Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.&#xD;
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Jeong Min Lee</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>82-2-2072-3154</phone>
      <email>jmsh@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

